Related Experiment Video

Updated: Oct 9, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Distinctive effects of glicentin, GLP-1 and GLP-2 on adaptive response to massive distal small intestine resection in

Y Hirotani1, K Yamamoto, C Yanaihara

  • 1Laboratory of Pharmaceutical Sciences, Osaka University Graduate School of Medicine, D17 Suita, Osaka 565-0871, Japan. yosihiko@drug.med.osaka-u.ac.jp

Annals of the New York Academy of Sciences
|February 24, 2001
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Roux-en-Y Gastric Bypass Operation in Rats07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...